Neuropathic pain is pain caused by damage or disease affecting the nerves themselves, rather than by an injury to the tissues those nerves serve. It affects an estimated 7–10% of the general population and feels distinctly different from the ache of a sprained ankle or a sore muscle. People often describe it as burning, electric, shooting, or stabbing, and it can arise from conditions as varied as diabetes, shingles, and chemotherapy. Because the nervous system itself is malfunctioning, standard painkillers like ibuprofen tend to be ineffective, and treatment relies on a different set of drugs and strategies altogether.
What Neuropathic Pain Actually Feels Like
The hallmark of neuropathic pain is that the sensations it produces don’t match what’s happening to your body. You might feel a sharp, burning jolt with no obvious trigger, or a light brush of clothing against your skin might register as intensely painful. Clinicians break these abnormal sensations into two broad categories. Allodynia is pain from something that normally wouldn’t hurt at all, like a bedsheet dragging across your feet. Hyperalgesia is an amplified pain response to something that would usually cause only mild discomfort, like a gentle pinprick feeling like a stab. Both of these affect roughly 15–50% of people with neuropathic pain, and they can be triggered by touch, pressure, cold, or heat.1PubMed. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms
Beyond allodynia and hyperalgesia, people with neuropathic pain frequently report tingling, numbness, pins-and-needles sensations, and spontaneous shooting or electric-shock-like pains that come and go without warning. Some experience a constant deep burning that never fully goes away, punctuated by sharper flare-ups. The pain often worsens at night, which is part of why sleep problems are so common in this population. The specific pattern depends on the underlying cause and which nerves are affected, but the unifying theme is that the nervous system is generating pain signals on its own, independent of any ongoing tissue damage.
Common Causes
A wide range of conditions can injure or disrupt nerves badly enough to trigger neuropathic pain. Some damage peripheral nerves (the wiring outside the brain and spinal cord), while others affect the central nervous system directly.
Diabetes
Diabetic neuropathy is one of the most common causes worldwide. Chronically elevated blood sugar damages small blood vessels that supply nerves, starving them of oxygen and nutrients. Endothelial dysfunction, the breakdown of the cells lining those blood vessels, is the common thread connecting the metabolic and vascular damage that diabetes inflicts on nerves.2PubMed. Ischemia and diabetic neuropathy The result is usually a “stocking-glove” pattern of burning, tingling, and numbness that starts in the feet and gradually works its way upward.
Shingles and Postherpetic Neuralgia
Anyone who had chickenpox as a child carries the varicella zoster virus in a dormant state within their nerve cell clusters. When the virus reactivates, it causes shingles, a painful rash along the path of a single nerve. In some people, the pain doesn’t go away after the rash heals. This lingering pain, called postherpetic neuralgia, is defined as pain still present a month or more after the rash appeared, and it occurs predominantly in older adults and people with weakened immune systems.3Neuropathic Pain. Herpes Zoster and Postherpetic Neuralgia Postherpetic neuralgia can persist for months or even years.
Chemotherapy
Chemotherapy-induced peripheral neuropathy is a frustrating side effect of cancer treatment. Several classes of cancer drugs are known to damage sensory nerves, with platinum-based agents, taxanes, and thalidomide being among the most neurotoxic.4PubMed Central. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy The damage involves oxidative stress, nerve fiber degeneration, and inflammation, often leading to numbness and pain in the hands and feet that can outlast the treatment itself.5PubMed Central. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy For some cancer survivors, this becomes a permanent problem.
Central Nervous System Injury and Disease
Neuropathic pain doesn’t always start in the peripheral nerves. Damage to the brain or spinal cord can produce it too. Among patients treated by neurologists, central neuropathic pain develops most often after spinal cord injury, in multiple sclerosis, or following a stroke.6PubMed. Central Neuropathic Pain In these cases, the pain-processing circuits within the brain or spinal cord themselves are misfiring.
Trigeminal Neuralgia
Trigeminal neuralgia deserves special mention because it’s among the most severe pain conditions known. It causes sudden, shock-like jolts of pain in the face, typically triggered by everyday actions like chewing, talking, or even a gust of wind. The cause is frequently a blood vessel pressing against the trigeminal nerve near the brainstem.7PubMed. MRI of the Trigeminal Nerve in Patients With Trigeminal Neuralgia Secondary to Vascular Compression Because arteries stiffen and become more tortuous with age, this compression becomes more likely as people get older, eventually causing the nerve’s protective coating to break down.8PubMed Central. Arterial compression of nerve is the primary cause of trigeminal neuralgia
Why Damaged Nerves Keep Firing
Understanding why neuropathic pain persists, often long after the original injury has healed, comes down to changes in how nerve cells behave. When nerves are injured, the damaged fibers can start generating electrical signals on their own, without any input from the outside world. These spontaneous bursts of activity, called ectopic discharges, appear to be important in the earliest stages of neuropathic pain. In animal models, ectopic discharges were strongly linked to pain sensitivity in the first day after nerve injury, but that correlation faded over the following two weeks, suggesting other mechanisms take over.9PubMed. Ectopic discharges from injured nerve fibers are highly correlated with tactile allodynia only in early, but not late, stage in rats with spinal nerve ligation
One of the more striking changes involves the large nerve fibers that normally carry touch and vibration signals. After injury, these fibers can undergo what researchers call phenotypic switching: they start behaving like pain-signaling neurons, both in the electrical patterns they fire and in the chemical messengers they release. This means a light touch stimulus gets routed into pain pathways in the spinal cord, which helps explain why allodynia is so common.10PubMed. Ectopic discharge in Abeta afferents as a source of neuropathic pain
As the condition becomes chronic, the spinal cord and brain themselves change. Neurons in the spinal cord become hypersensitive, amplifying incoming signals in a process called central sensitization. Specific receptors in the spinal cord play a key role in establishing this heightened state, essentially turning up the volume on pain signals.11Experimental Neurology. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain Immune cells in the spinal cord called microglia also contribute. Research shows that microglial activation persists for months after nerve injury. In the chronic phase, it is specifically the interaction between microglia and spinal cord neurons, rather than the original inflammatory response, that maintains pain hypersensitivity.12Pain. Spinal microglia are required for long-term maintenance of neuropathic pain This distinction matters because it points toward different treatment targets for early versus late-stage pain.
How Neuropathic Pain Is Diagnosed
There is no single blood test or scan that definitively says “this is neuropathic pain.” Diagnosis relies heavily on the pattern of symptoms, the patient’s medical history, and targeted physical examination. Validated screening questionnaires have become a practical frontline tool, helping clinicians identify neuropathic pain based on self-reported symptoms. These questionnaires have been translated and validated across many languages and can help create symptom-based profiles that predict which treatments are likely to work best for a given patient.13PubMed. Diagnosis and assessment of neuropathic pain through questionnaires
When more objective confirmation is needed, quantitative sensory testing can measure how well both large and small nerve fibers are functioning, testing for both loss of sensation and abnormal heightened responses like allodynia. The limitation is that it depends on the patient’s cooperation and focus, making it semi-objective at best.14PubMed Central. Diagnosis and assessment of neuropathic pain For small fiber neuropathy specifically, where standard nerve conduction studies come back normal because they only test large fibers, a skin punch biopsy is the recommended objective test. A tiny sample of skin is taken and the density of small nerve fibers within it is counted. Reduced density at the lower leg, compared to established reference ranges, has a diagnostic accuracy of about 88%.15Archives of Neurology. Epidermal Nerve Fiber Density: Normative Reference Range and Diagnostic Efficiency16PubMed Central. Intraepidermal Nerve Fiber Density as Measured by Skin Punch Biopsy as a Marker for Small Fiber Neuropathy
First-Line Medications
Standard painkillers aren’t the answer here. Anti-inflammatory drugs and even many opioids do a poor job against neuropathic pain. Instead, the drugs that work best were originally developed for other conditions entirely.
Gabapentinoids, specifically pregabalin and gabapentin, are among the most widely prescribed first-line treatments. Despite their names suggesting a connection to the brain chemical GABA, they actually work by binding to a specific part of voltage-gated calcium channels in nerve cells. By reducing calcium flow into nerve terminals, they dial down the release of excitatory chemical messengers and calm overactive nerve signaling.17Frontiers in Cellular Neuroscience. Pregabalin as a Pain Therapeutic: Beyond Calcium Channels Clinical trials have shown they provide meaningful pain relief across multiple types of neuropathic pain, including diabetic neuropathy.18PubMed Central. Calcium Channel α(2)δ Ligands Mirogabalin, Pregabalin, and Gabapentin: Advancements in Diabetic Peripheral Neuropathic Pain Therapeutics Side effects, including drowsiness and dizziness, are the main limitation.
Certain antidepressants, particularly duloxetine and amitriptyline, are the other major first-line option. Their pain-relieving effect has nothing to do with improving mood. Instead, they boost levels of norepinephrine in the spinal cord, which activates pathways that directly inhibit pain signaling from damaged nerves.19PubMed Central. Analgesic Mechanisms of Antidepressants for Neuropathic Pain Animal research has shown that both duloxetine and amitriptyline reduced touch-evoked pain and temperature hypersensitivity in nerve-injured animals, and that this analgesic effect was abolished when spinal adrenergic receptors were blocked, confirming the mechanism works in the spinal cord itself.20ACS Chemical Neuroscience. Duloxetine and Amitriptyline Reduce Neuropathic Pain by Inhibiting Primary Sensory Input to Spinal Dorsal Horn Neurons via α1- and α2-Adrenergic Receptors Serotonin and dopamine may reinforce this norepinephrine-driven pain suppression.
Topical Treatments for Localized Pain
When neuropathic pain is confined to a specific area of the body, topical treatments can offer relief with far fewer systemic side effects. Lidocaine patches (5%) and high-concentration capsaicin patches (8%) are the two best-supported options. In older adults, who are particularly vulnerable to the cognitive fog, dizziness, and constipation caused by oral medications, topical treatments are especially appealing because they deliver the drug locally with minimal absorption into the bloodstream.21PubMed. Topical Treatment of Localized Neuropathic Pain in the Elderly Expert consensus has noted that these patches maintain their effectiveness over long-term use and can be combined safely with other pain medications.22PubMed Central. Localized neuropathic pain: an expert consensus on local treatments
Spinal Cord Stimulation
For people whose neuropathic pain hasn’t responded adequately to medications, spinal cord stimulation is an interventional option with a growing evidence base. A small device is implanted that delivers mild electrical pulses to the spinal cord, essentially interfering with pain signals before they reach the brain. It’s considered a well-established treatment for several types of chronic neuropathic pain, though it remains underutilized; many general practitioners and even some specialists are slow to refer patients for it.23PubMed Central. Spinal Cord Stimulation for Neuropathic Pain: Current Trends and Future Applications
In a randomized trial of patients with failed back surgery syndrome, a common cause of chronic neuropathic pain, about half of those receiving spinal cord stimulation achieved meaningful pain relief at six months, compared to only 9% of those managed with medications alone. The stimulation group also reported better quality of life and greater functional capacity.24PubMed. Spinal cord stimulation versus conventional medical management for neuropathic pain A newer variation targets the dorsal root ganglion, a cluster of nerve cell bodies near the spinal cord, and has shown pain reductions of roughly 56% at one year, with particularly strong results for foot pain.25PubMed. One-year outcomes of spinal cord stimulation of the dorsal root ganglion in the treatment of chronic neuropathic pain
Cognitive Behavioral Therapy and Rehabilitation
Neuropathic pain is not purely a nerve-wiring problem. How the brain processes and interprets pain signals is influenced by attention, mood, expectations, and learned behaviors. Cognitive behavioral therapy addresses these psychological dimensions and has been studied across a range of neuropathic conditions. An evidence mapping based on systematic reviews found that CBT showed “potentially better” results in certain populations, particularly people with neuropathic pain after spinal cord injury. However, results overall were mixed, and CBT did not appear to offer clear advantages over other forms of psychotherapy like relaxation therapy.26PubMed Central. Evidence Mapping Based on Systematic Reviews of Cognitive Behavioral Therapy for Neuropathic Pain That said, studies that tracked patients over time generally found that benefits accumulated during follow-up, suggesting the skills learned in CBT continue to help after formal treatment ends.
Physical rehabilitation techniques, graded exercise, and desensitization approaches also play a role, particularly for helping people regain function and reduce the avoidance behaviors that chronic pain tends to breed. The research base for physical therapy in neuropathic pain is still catching up, but the direction of evidence suggests these approaches will take on a larger role in management over time.27American Journal of Physical Medicine & Rehabilitation. Physical Therapy Modalities and Rehabilitation Techniques in the Management of Neuropathic Pain
Cannabinoids and Where They Fit
Cannabis-based treatments get a lot of attention for pain, and the evidence for neuropathic pain specifically is more legitimate than for many other pain types. Meta-analyses and systematic reviews generally support that cannabinoids provide modest relief for chronic neuropathic pain. But the word “modest” is doing real work in that sentence. The effect size is smaller than what gabapentinoids and antidepressants typically deliver. Current expert opinion positions cannabinoids as a consideration only when first-line and second-line treatments alone are insufficient, either as an add-on or for refractory cases.28PubMed Central. Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks
One area where cannabinoids look more promising is as a potential way to reduce opioid use. Evidence supports an “opioid-sparing” effect, and unlike opioids, cannabinoids do not carry the risk of fatal respiratory depression. The side effects, primarily dizziness and drowsiness, are moderate and manageable for most people.29International Journal of Innovative Technologies in Social Science. ADVANCES IN CANNABINOID-BASED PAIN MANAGEMENT: EFFICACY AND EVIDENCE They are best thought of as one piece of a broader pain management strategy rather than a standalone cure.
Why Some People Are More Susceptible
Not everyone with the same nerve injury develops the same level of pain. Genetics plays a measurable role. A large genetic study across three cohorts identified a specific variant at chromosome 12q23.1 that was associated with increased susceptibility to neuropathic pain, with carriers having roughly 68% higher odds of developing it.30JAMA Network Open. Association of Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility Animal research tells a similar story: rats selectively bred for high spontaneous pain also showed greater sensitivity to touch-evoked and heat-evoked pain, and this predisposition varied with sex and age at the time of nerve injury.31PubMed. Unity vs. diversity of neuropathic pain mechanisms: Allodynia and hyperalgesia in rats selected for heritable predisposition to spontaneous pain
At the extreme end, rare inherited conditions caused by mutations in sodium channel genes can produce neuropathic pain syndromes outright, including some forms of small fiber neuropathy.32PubMed Central. Genetic studies of human neuropathic pain conditions: a review33PubMed. Neuropathische Schmerzsyndrome und Kanalopathien These are uncommon, but they’ve been scientifically valuable because they confirm how critical sodium channels are to pain processing, and they’ve pointed drug developers toward specific targets for new treatments.
Neuropathic Pain and Sleep
The relationship between neuropathic pain and sleep is a vicious circle that many patients recognize all too well. Pain disrupts sleep by fragmenting sleep cycles, reducing time in deep restorative stages, and causing frequent nighttime awakenings. Poor sleep then lowers the body’s pain threshold, making the next day’s pain worse. Research suggests this goes beyond simple discomfort: persistent pain signals can actually desynchronize circadian rhythms, the body’s internal clock. In the other direction, a disrupted circadian clock appears to worsen pain perception and may contribute to the shift from acute to chronic pain through altered neuroinflammation.34Nature and Science of Sleep. What Links Sleep and Neuropathic Pain?: A Literature Review on the Neural Circuits for Sleep and Pain Control Addressing sleep quality, whether through medication timing, sleep hygiene, or direct treatment of insomnia, is an underappreciated piece of neuropathic pain management.
The Placebo Problem in Drug Development
If you’ve wondered why new neuropathic pain drugs keep failing in clinical trials despite promising early results, part of the answer is surprisingly strange. Research has shown that placebo responses in neuropathic pain trials have been climbing steadily over the years, while the actual drug responses have stayed about the same. The result is a shrinking gap between drug and placebo arms, making it harder and harder for trials to show that a new medication works.35PubMed. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain This doesn’t mean the drugs are useless; it means the trial environment itself has changed in ways that make it difficult to detect real effects. Larger trial sizes, longer durations, and the growing expectation among participants that they might be receiving an active treatment all likely contribute.36PubMed. Placebo effects in neuropathic pain conditions
This matters practically because it slows the pipeline of new treatments reaching patients. Researchers are working on strategies to address this, including better patient selection, enriched enrollment designs, and more sensitive endpoints. But for now, it’s one reason the first-line medications for neuropathic pain haven’t changed dramatically in years, and why promising drug targets, like selective sodium channel blockers aimed at specific channels involved in pain, have had trouble making it through clinical trials to approval.37PubMed. Novel sodium channel antagonists in the treatment of neuropathic pain